

UCB announces acquisition of IMIDomics' Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)

- **UCB acquires IMIDomics' Patient Insight Business, gaining access to one of the world's most comprehensive multi-omic datasets for immune-mediated inflammatory diseases**
- **Patient Insight Business enhances UCB's ability to identify novel drug targets, discover responder biomarkers, and design molecularly informed patient-stratification approaches**

Brussels, Belgium, 1st May 2026 - UCB (Euronext: UCB) and IMIDomics announced today that UCB has acquired the Patients Insights Business of IMIDomics. This strategic acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunology, significantly enhancing the company's ability to accelerate precision--driven therapeutic discovery and development.

Alistair Henry, Executive Vice President & Chief Scientific Officer at UCB said, "*The acquisition of IMIDomics' Patient Insight Business represents a significant step in our strategy to build the most robust, human data--driven platform in immune-mediated diseases. IMIDomics has spent a decade assembling a dataset and network that are simply not replicable in today's environment. Integrating these capabilities and welcoming the highly skilled IMIDomics team and the insight they bring will elevate our ability to discover and develop medicines that are truly informed by patient biology.*"

IMIDomics' Patient Insight Business, built on more than 18 years of clinical and molecular data generation, integrates epidemiological information, detailed clinical histories, imaging data, multi-omic profiles, and longitudinal patient samples collected through a robust clinical network of more than 300 investigators and 130+ recruiting centers. The Patient Insights Business is powered by samples stored in the IMID Biobank at the Vall d'Hebron Institute of Research (VHIR) in Barcelona, one of the most comprehensive IMID-focused biobanks globally, with contributions from over 17,000 patients.

Professor Sara Marsal Founder and Chief Medical Officer of IMIDomics Inc, said, "*Our mission has always been to bring the patient, through their biology, clinical journeys, and data, into every stage of drug development. UCB is the ideal partner to scale that mission. With their scientific depth and commitment to innovation, we are confident the Patient Insight Engine will continue to unlock meaningful breakthroughs for people living with IMIDs.*"

Under the terms of the acquisition, UCB will gain access to IMIDomics' skilled personnel and laboratories, proprietary genetics and omics datasets, analytic platform, and established partnerships, including the contractual framework enabling continued access to VHIR-controlled human biological samples and associated data. These assets form the backbone of IMIDomics' precision medicine platform, which applies advanced biostatistics, machine learning, and AI to uncover new therapeutic targets, responder biomarkers, and disease-subtype insights that can meaningfully de-risk and accelerate drug development.

Financial details of the agreement were not disclosed.



About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on X: @UCB_news

Forward-looking statements

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

About IMIDomics

IMIDomics is dedicated to discovering and developing first-in-class medicines for immune-mediated inflammatory diseases (IMIDs), particularly for patients without treatment options or unresponsive to current treatments. The company's proprietary Clinical Discovery Engine™ integrates comprehensive longitudinal clinical, epidemiological, and biomolecular data from IMID patients, enabling the identification of disease mechanisms and the development of precision medications which increase the probability of success (PoS).





UCB News

Partnering with the Spanish IMID Clinical Consortium and the Vall d'Hebron Institute of Research (VHIR), IMIDomics is uniquely positioned to deliver the next generation of IMID therapies.

For further information, contact UCB:

Global R&D Communications
Scott Fleming
T: +44 7702777738
Scott.fleming@ucb.com

Corporate Communications, Media Relations
Laurent Schots
T +32.2.559.92.64
laurent.schots@ucb.com

Investor Relations
Sahar Yazdian/. Yvonne Naughton
T +32.2.559.91.37 / + 44.175.344.7521
Email sahar.yazdian@ucb.com/ yvonne.naughton@ucb.com

